	US 12,403,140 B2
	Pharmaceutical compositions of nilotinib
Paras P. Jain, Maharashtra (IN); Ajay Kumar Singh, Princeton, NJ (US); Keerthi Priya, Telangana (IN); Girish Kumar Jain, Maharashtra (IN); Girish G. Kore, Maharashtra (IN); Sandeep Jain, Madhya Pradesh (IN); and Hanimi Reddy Bapatu, Telangana (IN)
Assigned to AZURITY PHARMACEUTICALS, INC., Woburn, MA (US)
Filed by AZURITY PHARMACEUTICALS, INC., Woburn, MA (US)
Filed on Sep. 15, 2023, as Appl. No. 18/468,266.
Application 18/468,266 is a continuation of application No. 16/953,728, filed on Nov. 20, 2020.
Application 16/953,728 is a continuation of application No. 16/793,833, filed on Feb. 18, 2020, granted, now 10,874,671, issued on Dec. 29, 2020.
Claims priority of application No. 201941006393 (IN), filed on Feb. 18, 2019.
Prior Publication US 2024/0009188 A1, Jan. 11, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/4985 (2006.01); A61K 9/10 (2006.01); A61K 9/20 (2006.01)

CPC A61K 31/4985 (2013.01) [A61K 9/10 (2013.01); A61K 9/2095 (2013.01)]

11 Claims

1. A pharmaceutical composition comprising:

(i) nilotinib tartrate;

(ii) pharmaceutically acceptable carrier selected from the group consisting of hydroxypropyl methyl cellulose acetate succinate (HPMC-AS), polyvinyl pyrrolidine and vinyl acetate (PVP/VA) copolymer, hydroxypropyl methylcellulose phthalate (HPMCP), hydroxypropyl methylcellulose, (HPMC), polyethylene glycol (PEG), hydroxypropyl cellulose (HPC), carboxymethyl cellulose (CMC), polyvinyl pyrrolidine (PVP), and combinations thereof; and

(iii) one or more pharmaceutically acceptable excipients;

wherein an administered amount equivalent to nilotinib is about 50% less than a dose required for delivering a therapeutically effective amount equivalent to nilotinib in a fasted state using a reference formulation.